Evidence map›Paper›PMID 33228974›Full record

SynthesisClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.

Ali Rostami, Mahdi Sepidarkish, Mariska M G Leeflang, Seyed Mohammad Riahi, Malihe Nourollahpour Shiadeh, Sahar Esfandyari, Ali H Mokdad, Peter J Hotez, Robin B Gasser

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

228 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  6. Pooled it
  7. Returning to Work after the COVID-19 Pandemic Earthquake: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Update on SARS-CoV-2 seroprevalence: regional and worldwide.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  11. Pooled it
  12. The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Pooled it
  13. High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  14. Pooled it
  15. Trial
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

168 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali RostamiInfectious Diseases and Tropical Medicine Research Centre, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Electronic address: alirostami1984@gmail.com.
Mahdi SepidarkishDepartment of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.
Mariska M G LeeflangDepartment of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC/University of Amsterdam, Amsterdam, the Netherlands.
Seyed Mohammad RiahiCardiovascular Diseases Research Center, Department of Epidemiology and Biostatistics, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Malihe Nourollahpour ShiadehSexual and Reproductive Health Research Centre, Mazandaran University of Medical Sciences, Sari, Iran.
Sahar EsfandyariDepartment of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Ali H MokdadInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Department of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
Robin B GasserDepartment of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: robinbg@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCOVID-19 has been arguably the most important public health concern worldwide in 2020, and efforts are now escalating to suppress or eliminate its spread. In this study we undertook a meta-analysis to estimate the global and regional seroprevalence rates in humans of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and to assess whether seroprevalence is associated with geographical, climatic and/or sociodemographic factors.

methodsWe systematically reviewed PubMed, Scopus, Embase, medRxiv and bioRxiv databases for preprints or peer-reviewed articles (up to 14 August 2020). Study eligibility criteria were population-based studies describing the prevalence of anti-SARS-CoV-2 (IgG and/or IgM) serum antibodies. Participants were people from different socioeconomic and ethnic backgrounds (from the general population), whose prior COVID-19 status was unknown and who were tested for the presence of anti-SARS-CoV-2 serum antibodies. We used a random-effects model to estimate pooled seroprevalence, and then extrapolated the findings to the global population (for 2020). Subgroup and meta-regression analyses explored potential sources of heterogeneity in the data, and relationships between seroprevalence and sociodemographic, geographical and/or climatic factors.

resultsIn total, 47 studies involving 399 265 people from 23 countries met the inclusion criteria. Heterogeneity (I

conclusionsThis study showed that SARS-CoV-2 seroprevalence varied markedly among geographic regions, as might be expected early in a pandemic. Longitudinal surveys to continually monitor seroprevalence around the globe will be critical to support prevention and control efforts, and might indicate levels of endemic stability or instability in particular countries and regions.

Indexed as

Global HealthAdultAntibodies, ViralChildClimateCOVID-19COVID-19 Serological TestingFemaleGeographyHumansMaleSARS-CoV-2Seroepidemiologic StudiesSocioeconomic FactorsTime FactorsAntibodies, ViralCOVID-19General populationGlobal seroprevalenceMeta-analysisSARS-CoV-2Serum antibodies (IgG and/or IgM)Subgroup analyses

Identifiers

PMID33228974
PMCPMC7584920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.